Journal
CELLS
Volume 10, Issue 7, Pages -Publisher
MDPI
DOI: 10.3390/cells10071622
Keywords
primary sclerosing cholangitis; aryl hydrocarbon receptor; indole-3-carboxaldehyde; mucosal barrier; microbiota
Categories
Funding
- Italian Cystic Fibrosis Research Foundation [ERC-2018-PoC-813099]
- [24/2018]
Ask authors/readers for more resources
The study shows that localized delivery of 3-IAld in the gut can modulate the intestinal microbiota and activate specific pathways to restore mucosal integrity, thereby alleviating hepatic inflammation and fibrosis caused by PSC.
Primary sclerosing cholangitis (PSC) is a long-term liver disease characterized by a progressive course of cholestasis with liver inflammation and fibrosis. Intestinal barrier dysfunction has been implicated in the pathogenesis of PSC. According to the leaky gut hypothesis, gut inflammation alters the permeability of the intestinal mucosa, with the translocation of gut-derived products that enter the enterohepatic circulation and cause hepatic inflammation. Thus, the administration of molecules that preserve epithelial barrier integrity would represent a promising therapeutic strategy. Indole-3-carboxaldehyde (3-IAld) is a microbial-derived product working at the interface between the host and the microbiota and is able to promote mucosal immune homeostasis in a variety of preclinical settings. Herein, by resorting to a murine model of PSC, we found that 3-IAld formulated for localized delivery in the gut alleviates hepatic inflammation and fibrosis by modulating the intestinal microbiota and activating the aryl hydrocarbon receptor-IL-22 axis to restore mucosal integrity. This study points to the therapeutic potential of 3-IAld in liver pathology.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available